Von Willebrand Disease Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Von Willebrand Disease Treatment Market is Segmented by Disease Type (Type 1, Type 2, Type 3, and Acquired VWD), Treatment Type (Desmopressin, Replacement Therapies, Clot-Stabilizing, and Other Treatment Types), Route of Administration (Oral, Injection, and Other Routes of Administration), and Geography (North America, Europe, Asia Pacific, Middle East and Africa, and South America). The report offers the market sizes and forecasts in terms of value (USD million) for the above segments.

Market Snapshot

von willebrand disease treatment market overview
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 6.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Von Willebrand disease treatment market is expected to register a CAGR of 6.5% during the forecast period (2022-2027).

The COVID-19 pandemic has significantly impacted the Von Willebrand disease treatment market. For instance, as per a September 2021 published article titled, “Role of von Willebrand Factor in COVID-19 Associated Coagulopathy," patients with COVID-19 have significantly elevated levels of the Von Willebrand factor (vWF) antigen, contributing to an increased risk of thrombosis seen in COVID-19 associated coagulopathy (CAC). As per the same source, the high levels of both vWF antigen and activity have been clinically correlated with worse outcomes. Thus, the demand for Von Willebrand disease treatment is anticipated to rise, thereby contributing to market growth. On the other hand, the lack of awareness and the high cost of the treatment are the factors hindering the market growth.

The major factors fueling the market growth are the increase in patient assistance programs and the growing healthcare expenditure.

In July 2021, the PAN Foundation opened a new patient assistance program for people living with the Von Willebrand disease. The patients who qualify for this program receive USD 10,200 per year in financial assistance to pay for the deductibles, co-pays, and coinsurance costs associated with the treatment for the disease. Another initiative is the Octapharma Co-Pay Assistance Program. This program is available through Factor My Way and provides eligible patients with significant savings on some of the costs associated with their treatment. Such programs propel the demand for the treatment of the Von Willebrand disease, thereby contributing to the growth of the market.

Thus, owing to the abovementioned factors, the market is expected to show growth over the forecast period. However, lack of awareness and high cost of treatment may hamper the growth of the market.

Scope of the Report

As per the scope of the report, Von Willebrand disease (VWD) is a genetic disorder that delays the process of blood clotting. It is generally caused by a missing or defective Von Willebrand factor (VWF), a clotting protein. The market is segmented by disease type (Type 1, Type 2, Type 3, and Acquired VWD), treatment type (desmopressin, replacement therapies, clot-stabilizing, and other treatment types), route of administration (oral, injection, and other routes of administration), and geography (North America, Europe, Asia Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (USD million) for the above segments.

By Disease Type
Type 1
Type 2
Type 3
Acquired VWD
By Treatment Type
Desmopressin
Replacement Therapies
Clot-stabilizing Medications
Other Treatment Types
By Route of Administration
Oral
Injection
Other Routes of Administration
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Replacement Therapy Segment Expected to Register Significant Growth Over the Forecast Period

The replacement therapy segment is anticipated to witness significant growth. Replacement therapy is referred to as the therapy involving the supply of a substance (such as a hormone or nutrient) lacking in or lost from the body. The major factors fueling the segment's growth are the number of people with Von Willebrand disease and the increasing number of product approvals.

As per the Annual Global Survey by the World Hemophilia Federation, in 2020, the total number of people identified with the Von Willebrand disease globally was 84,197. In addition, several market players are engaged in obtaining approvals for replacement therapies for the treatment of the Von Willebrand disease. For instance, in June 2021, Takeda Pharmaceutical Company Limited reported that the United States Food and Drug Administration (FDA) had accepted the supplemental Biologics License Application (sBLA) for VONVENDI [von Willebrand factor (Recombinant)] for review. This is meant for prophylactic treatment to prevent or reduce the frequency of bleeding episodes in adults (aged 18 years and older) with von Willebrand disease. 

Thus, due to the above-mentioned factors, the segment is expected to witness significant growth over the forecast period.

Number of People with Von Willebrand Disease (in thousands), Global, 2020

North America Dominates the Market and Expected to do Same in the Forecast Period

Within North America, the United States holds the major share of the market. The major factors contributing to the market growth in the United States are the rising incidence of Von Willebrand disease, the growing number of strategic initiatives, and the growing number of patient assistance programs.

As per the Annual Global Survey by the World Hemophilia Federation, in 2020, the total number of people identified with Von Willebrand disorder in the United States was 8,919. Also, as per an April 2021 update by the Centers for Disease Control and Prevention (CDC), Von Willebrand disease is the most common bleeding disorder in the country. 3.2 million people (or around one person in every 100 people) in the United States have the disease. Therefore, there is a significant demand for the treatment of this disease in the United States, which contributes to the market growth.

There are several initiatives to raise awareness of the Von Willebrand disease. For instance, in August 2020, the National Hemophilia Foundation and Takeda partnered with Alex Borstein to raise awareness regarding the Von Willebrand disease.

Thus, due to the above-mentioned factors, the region is expected to witness significant growth during the forecast period.

von willebrand disease treatment market growth

Competitive Landscape

The Von Willebrand disease treatment market is competitive, with the presence of many global players. The most prominent players in the market are Bayer AG, CSL Behring, Ferring Pharmaceuticals, Grifols, Octapharma AG, Pfizer, Sanofi, Sun Pharmaceutical, and Takeda.

Recent Developments

  • In April 2022, Octapharma became a Gold Sponsor of the upcoming World Federation of Haemophilia (WFH) 2022 World Congress, taking place from May 8 to 11, 2022. Octapharma will highlight key unmet needs of people living with von Willebrand disease (VWD) during a live symposium.
  • In January 2022, Takeda received United States Food and Drug Administration (FDA) approved VONVENDI [von Willebrand Factor (Recombinant)] for routine prophylaxis treatment in patients with severe type 3 von Willebrand disease receiving on-demand therapy.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increase in Patient Assistance Programs

      2. 4.2.2 Growing Healthcare Expenditure

    3. 4.3 Market Restraints

      1. 4.3.1 Lack of Awareness

      2. 4.3.2 High Cost of Treatment

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 5.1 By Disease Type

      1. 5.1.1 Type 1

      2. 5.1.2 Type 2

      3. 5.1.3 Type 3

      4. 5.1.4 Acquired VWD

    2. 5.2 By Treatment Type

      1. 5.2.1 Desmopressin

      2. 5.2.2 Replacement Therapies

      3. 5.2.3 Clot-stabilizing Medications

      4. 5.2.4 Other Treatment Types

    3. 5.3 By Route of Administration

      1. 5.3.1 Oral

      2. 5.3.2 Injection

      3. 5.3.3 Other Routes of Administration

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany

        2. 5.4.2.2 United Kingdom

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 CSL Behring

      2. 6.1.2 Ferring Pharmaceuticals

      3. 6.1.3 Grifols SA

      4. 6.1.4 Octapharma AG

      5. 6.1.5 Pfizer Inc.

      6. 6.1.6 Sanofi SA

      7. 6.1.7 Takeda Pharmaceutical Company Ltd

      8. 6.1.8 Bio Products Laboratory Ltd

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape Covers Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Von Willebrand Disease Treatment Market market is studied from 2019 - 2027.

The Global Von Willebrand Disease Treatment Market is growing at a CAGR of 6.5% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

CSL Behring, Grifols, S.A., Takeda Pharmaceutical Company Ltd, Octapharma AG, Bio Products Laboratory Ltd. are the major companies operating in Global Von Willebrand Disease Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!